• TH
    • EN
    • Register
    • Login
    • Forgot Password
    • Help
    • Contact
  • Register
  • Login
  • Forgot Password
  • Help
  • Contact
  • EN 
    • TH
    • EN
View Item 
  •   Home
  • สถาบันวิจัยระบบสาธารณสุข (สวรส.) - Health Systems Research Institute (HSRI)
  • Research Reports
  • View Item
  •   Home
  • สถาบันวิจัยระบบสาธารณสุข (สวรส.) - Health Systems Research Institute (HSRI)
  • Research Reports
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

COVID-19 Vaccine Effectiveness in Thailand: a Real World Study (2nd Year)

ภาสกร ศรีทิพย์สุโข; Paskorn Sritipsukho; บุญยิ่ง ศิริบำรุงวงศ์; Boonying Siribumrungwong; พิชญ ตันติยวรงค์; Pichaya Tantiyavarong; อารยา ศรัทธาพุทธ; Araya Satdhabudha; พรรณศจี ดำรงเลิศ; Pansachee Damronglerd; พีร์ จารุอำพรพรรณ; Peera Jaru-ampornpan;
Date: 2566-06
Abstract
We conducted a test negative case control study to assess the Vaccine Effectiveness (VE) of various vaccine regimens for preventing COVID-19 infection and its severity during the period when Omicron was the dominant causative virus in Thailand. All 8,600 individuals, aged ≥5 years, at risk for COVID-19 (Patient Under Investigation, PUI) who presented for nasopharyngeal real time polymerase chain reaction (RT-PCR) testing were prospectively enrolled at Thammasat University hospital during January to June 2022. There were 3,546 cases who were infected. For preventing omicron variant associated infections, the VE increased along with the increase in the number of vaccine dose and the four dose regimen (2 boosters) had the highest but only moderate VE. For preventing severity, the three and four dose regimens (1 and 2 boosters) had comparable high VE and their effectiveness was more durable than the two dose regimens. Significant protective factors to prevent infection were vaccine doses, female and healthcare personnel. Significant risk of infection included elderly, at least one chronic morbidity and household infection. Significant risk of severe COVID-19 was incomplete two dose vaccination, at least one chronic morbidity and elderly. Longcovid condition was prevalent after 6 months of COVID-19. It consisted of multi system symptoms. Weakness and neurological symptoms were the most common manifestations. Risk factors of longcovid condition were female, cough symptom at acute infection and severe COVID-19. Based on the study findings, current mass vaccination programs should focus on reducing COVID-19 severity and mandate at least one booster dose after primary series vaccines. The heterologous boosters with viral vector and mRNA vaccines were highly effective and can be used in individuals who had previously received the primary series of inactivated viral vaccine.
Copyright ผลงานวิชาการเหล่านี้เป็นลิขสิทธิ์ของสถาบันวิจัยระบบสาธารณสุข หากมีการนำไปใช้อ้างอิง โปรดอ้างถึงสถาบันวิจัยระบบสาธารณสุข ในฐานะเจ้าของลิขสิทธิ์ตามพระราชบัญญัติสงวนลิขสิทธิ์สำหรับการนำงานวิจัยไปใช้ประโยชน์ในเชิงพาณิชย์
Fulltext
Thumbnail
Name: hs2988.pdf
Size: 1.431Mb
Format: PDF
Download

User Manual
(* In case of download problems)

Total downloads:
Today: 0
This month: 0
This budget year: 2
This year: 1
All: 64
 

 
 


 
 
Show full item record
Collections
  • Research Reports [2469]

    งานวิจัย


DSpace software copyright © 2002-2016  DuraSpace
Privacy Policy | Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

HSRI Knowledge BankDashboardCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjectsSubjectsการบริการสุขภาพ (Health Service Delivery) [619]กำลังคนด้านสุขภาพ (Health Workforce) [99]ระบบสารสนเทศด้านสุขภาพ (Health Information Systems) [286]ผลิตภัณฑ์ วัคซีน และเทคโนโลยีทางการแพทย์ (Medical Products, Vaccines and Technologies) [125]ระบบการเงินการคลังด้านสุขภาพ (Health Systems Financing) [158]ภาวะผู้นำและการอภิบาล (Leadership and Governance) [1281]ปัจจัยสังคมกำหนดสุขภาพ (Social Determinants of Health: SDH) [228]วิจัยระบบสุขภาพ (Health System Research) [28]ระบบวิจัยสุขภาพ (Health Research System) [20]

DSpace software copyright © 2002-2016  DuraSpace
Privacy Policy | Contact Us | Send Feedback
Theme by 
Atmire NV